On Thursday, Johnson & Johnson announced that clinical trials of its new vaccine for Ebola virus will start from early 2015. The vaccine is based on the technology from Danish biotech firm Bavarian Nordic BAVA. CO.
The decision to initiate trials came at a time when initial human testing of a GlaxoSmithKline GSK. L vaccine is going to start from this month. In the autumn, a vaccine developed by Canadian government scientists and licensed to NewLink Genetics NLNK. O will be tested.